2605.02600 APS-DOAC: Transparent DOAC Suitability Risk-Context Stratification in Antiphospholipid Syndrome
## Abstract Anticoagulation in antiphospholipid syndrome (APS) remains clinically contentious because the convenience of direct oral anticoagulants (DOACs) is not matched by uniform safety across APS phenotypes. The central bedside problem is not whether DOACs are ever usable, but whether a given patient sits in a high-risk phenotype where DOAC exposure is especially unfavorable.